Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:34 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 7,436 matching trials from the live ClinicalTrials.gov search.
Filters: Aurora, Colorado Clear all
Completed Phase 2Phase 3 Interventional

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
View directory record Official record
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
57
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

NCT01928394
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Nivolumab, Ipilimumab, Cobimetinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
19
States / cities
Muscle Shoals, Alabama • Aurora, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 3, 2026, 7:34 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

NCT02979522
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine
Drug
Lead sponsor
Takeda
Industry
Eligibility
5 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 7:34 AM EST
Suspended Phase 1 Interventional

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

NCT05685602
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Gemcitabine Hydrochloride, Nab-paclitaxel
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 3, 2026, 7:34 AM EST
Active, not recruiting Phase 3 Interventional Results available

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LHRH agonist, surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
221
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Nov 3, 2026, 7:34 AM EST
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
495
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Completed No phase listed Observational

Study of Blood Samples From Newborns With Down Syndrome

NCT00959283
View directory record Official record
Conditions
Myeloid Proliferations Associated With Down Syndrome
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 90 Days
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 130 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 3, 2026, 7:34 AM EST
Completed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

NCT02561273
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Lenalidomide, Peripheral Blood Stem Cell Transplantation, Prednisone, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Nov 3, 2026, 7:34 AM EST
Completed Not applicable Interventional

The RAPID Trial: Assessing Point-of-care Influenza and Other Respiratory Virus Diagnostics

NCT03756753
View directory record Official record
Conditions
Respiratory Pathogens, Upper Respiratory Tract Illness, Lower Respiratory Tract Illness, Acute Respiratory Infection
Interventions
Results available to provider
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 18 Years
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 3, 2026, 7:34 AM EST
Completed Phase 2 Interventional Results available

Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer

NCT01439945
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Hot Flashes
Interventions
magnesium oxide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
283
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Aurora, Colorado + 192 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 3, 2026, 7:34 AM EST
Recruiting No phase listed Observational

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

NCT04098445
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 24 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
9
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT06919666
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
NT219
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 7:34 AM EST
Completed Not applicable Interventional

Characterizing Stray Energy Injuries During Robotic Surgery

NCT03477201
View directory record Official record
Conditions
Port-site Injury Caused by Stray Energy Transfer
Interventions
Laparoscopic robotic DaVinci assisted inguinal hernia repair, Standard laparoscopic inguinal hernia repair
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Nov 3, 2026, 7:34 AM EST
Not listed Phase 3 Interventional

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

NCT00715637
View directory record Official record
Conditions
Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Interventions
Daunorubicin and Cytarabine, Amonafide and Cytarabine
Drug
Lead sponsor
Antisoma Research
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
30
States / cities
Los Angelas, California • Los Angeles, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Nov 3, 2026, 7:34 AM EST
Terminated No phase listed Observational

Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)

NCT02769637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PPI treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Nov 3, 2026, 7:34 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics

NCT03092037
View directory record Official record
Conditions
Contraception
Interventions
Blood draw
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Nov 3, 2026, 7:34 AM EST
Completed Phase 2 Interventional Results available

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

NCT01466595
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Rifaximin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Nov 3, 2026, 7:34 AM EST
Terminated Not applicable Interventional Results available

Videofluoroscopic Swallowing Study (VFSS)

NCT03387267
View directory record Official record
Conditions
Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia, Alzheimer Disease, Dementia
Interventions
Dysphagia Detection System
Device
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Downey, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 3, 2026, 7:34 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

NCT03781167
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Nov 3, 2026, 7:34 AM EST
Terminated Phase 2 Interventional Results available

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

NCT00515099
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Antithymocyte globulin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Nov 3, 2026, 7:34 AM EST